Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Authors
Keywords
-
Journal
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-05
DOI
10.1007/s00270-021-03031-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Gastroenterology & Hepatology
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study
- (2019) Qiuhe Wang et al. JOURNAL OF HEPATOLOGY
- Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
- (2019) Huayu Yang et al. Frontiers in Oncology
- Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach
- (2019) Guohong Han et al. HEPATOLOGY
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply
- (2017) Christina Fitzmaurice et al. JAMA Oncology
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
- (2016) Riccardo Lencioni et al. HEPATOLOGY
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
- (2012) Seiki Miura et al. BMC CANCER
- Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis
- (2010) Christine Gauglhofer et al. HEPATOLOGY
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Immune Regulation of Cancer
- (2010) Mary L. Disis JOURNAL OF CLINICAL ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started